DK3047269T3 - DIAGNOSIS OF Fetal DISTRESS - Google Patents
DIAGNOSIS OF Fetal DISTRESS Download PDFInfo
- Publication number
- DK3047269T3 DK3047269T3 DK14772109.6T DK14772109T DK3047269T3 DK 3047269 T3 DK3047269 T3 DK 3047269T3 DK 14772109 T DK14772109 T DK 14772109T DK 3047269 T3 DK3047269 T3 DK 3047269T3
- Authority
- DK
- Denmark
- Prior art keywords
- uric acid
- sample
- distress
- samples
- salivary
- Prior art date
Links
- 206010016855 Foetal distress syndrome Diseases 0.000 title claims description 34
- 208000032943 Fetal Distress Diseases 0.000 title claims 8
- 238000003745 diagnosis Methods 0.000 title description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 79
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 45
- 229940116269 uric acid Drugs 0.000 claims description 45
- 230000035935 pregnancy Effects 0.000 claims description 32
- 201000011461 pre-eclampsia Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 210000003296 saliva Anatomy 0.000 claims description 22
- 238000012544 monitoring process Methods 0.000 claims description 16
- 230000009429 distress Effects 0.000 claims description 7
- 230000008774 maternal effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 206010070538 Gestational hypertension Diseases 0.000 claims description 5
- 208000004104 gestational diabetes Diseases 0.000 claims description 5
- 230000002028 premature Effects 0.000 claims description 5
- 206010051641 Amniorrhexis Diseases 0.000 claims description 4
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 4
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 4
- 208000002296 eclampsia Diseases 0.000 claims description 4
- 208000030941 fetal growth restriction Diseases 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 3
- 230000035487 diastolic blood pressure Effects 0.000 claims description 2
- 230000035488 systolic blood pressure Effects 0.000 claims description 2
- 206010049119 Emotional distress Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000006609 metabolic stress Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- 206010062936 Placenta Accreta Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000003793 prenatal diagnosis Methods 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 1
- 208000036818 High risk pregnancy Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 201000005608 severe pre-eclampsia Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316668.1A GB201316668D0 (en) | 2013-09-19 | 2013-09-19 | Diagnosis of foetal distress |
| PCT/EP2014/070053 WO2015040190A1 (en) | 2013-09-19 | 2014-09-19 | Diagnosis of foetal distress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3047269T3 true DK3047269T3 (en) | 2018-09-17 |
Family
ID=49553104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14772109.6T DK3047269T3 (en) | 2013-09-19 | 2014-09-19 | DIAGNOSIS OF Fetal DISTRESS |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160231306A1 (enExample) |
| EP (1) | EP3047269B1 (enExample) |
| JP (1) | JP6456394B2 (enExample) |
| CA (1) | CA2922894C (enExample) |
| DK (1) | DK3047269T3 (enExample) |
| ES (1) | ES2687971T3 (enExample) |
| GB (1) | GB201316668D0 (enExample) |
| WO (1) | WO2015040190A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3442415B1 (en) | 2016-04-14 | 2025-05-28 | Morgan Innovation & Technology Ltd | Methods for measuring the levels of analytes in body fluids |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313828D0 (en) * | 2003-06-16 | 2003-07-23 | Owen Smith Brian D O | Salivary urate for diagnosis of pre-eclampsia |
-
2013
- 2013-09-19 GB GBGB1316668.1A patent/GB201316668D0/en not_active Ceased
-
2014
- 2014-09-19 CA CA2922894A patent/CA2922894C/en active Active
- 2014-09-19 EP EP14772109.6A patent/EP3047269B1/en active Active
- 2014-09-19 WO PCT/EP2014/070053 patent/WO2015040190A1/en not_active Ceased
- 2014-09-19 US US15/023,002 patent/US20160231306A1/en not_active Abandoned
- 2014-09-19 DK DK14772109.6T patent/DK3047269T3/en active
- 2014-09-19 JP JP2016543421A patent/JP6456394B2/ja active Active
- 2014-09-19 ES ES14772109.6T patent/ES2687971T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2922894A1 (en) | 2015-03-26 |
| EP3047269A1 (en) | 2016-07-27 |
| WO2015040190A1 (en) | 2015-03-26 |
| JP6456394B2 (ja) | 2019-01-23 |
| CA2922894C (en) | 2022-05-03 |
| EP3047269B1 (en) | 2018-08-01 |
| US20160231306A1 (en) | 2016-08-11 |
| JP2016531305A (ja) | 2016-10-06 |
| GB201316668D0 (en) | 2013-11-06 |
| ES2687971T3 (es) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westgren et al. | Lactate compared with pH analysis at fetal scalp blood sampling: a prospective randomised study | |
| Morse et al. | Fetal growth screening by fundal height measurement | |
| Barber et al. | Contributing indications to the rising cesarean delivery rate | |
| JP7657195B2 (ja) | 収縮期血圧、血液パラメーター、およびこれらの組み合わせを含むバイタルサインを使用して敗血症を検出する方法 | |
| Wier et al. | Gestational age estimation on United States livebirth certificates: a historical overview | |
| Rabinowitz et al. | Pregnancy hypertension, blood pressure during labor, and blood lead levels. | |
| Vandenbroucke et al. | Chorioamnionitis following preterm premature rupture of membranes and fetal heart rate variability | |
| US20170052193A1 (en) | Fertility and pregnancy monitoring device and method | |
| Christiaens et al. | Validity of intrapartum diagnosis of fetal thrombocytopenia | |
| Kirkegaard et al. | Improved performance of first‐trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks | |
| Bhushan et al. | The reliability of neonatal head circumference measurement | |
| Buhling et al. | The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes | |
| DK3047269T3 (en) | DIAGNOSIS OF Fetal DISTRESS | |
| Landon et al. | Capillary blood glucose screening for gestational diabetes: a preliminary investigation | |
| Chamberlain | A re-examination of antenatal care | |
| Hamza et al. | Diagnostic Accuracy of Fetal Transverse Cerebellar Diameter as Independent Parameter in Diagnosis of Intrauterine Growth Restriction | |
| Bonacquisto | Antenatal screening: the first and second trimester | |
| Khalil et al. | Chorionicity and gestational diabetes mellitus in twin pregnancies in relation to placental weight | |
| JP7557709B2 (ja) | ストレスマーカ、ストレスレベル判定方法、および判定試薬 | |
| CN1865944A (zh) | 无创定量hcg检测方法 | |
| Liteanu et al. | Some biochemical indicators of the amniotic fluid-possible way for evaluation of the renal development | |
| Torki | Analysis of the Correlation Between Pregnancy Complications and Placental Histopathology: A Study of Samples from Shahid Sadoughi Hospital, Yazd, Iran (2013-2022) | |
| Hendrix et al. | outcomes in appropriate-for-gestational-age neonates: a retrospective cohort study | |
| Azzam et al. | Association between Glycemic Control and Birth Weight with Glycated Albumin in Women with Gestational Diabetes Mellitus | |
| Ilkovska et al. | Incidence of pregnancy chromosomal abnormalities detected by screening which include: fetal nuchal translucency thickness, maternal serum free beta human chorionic gonadotrophin hormone, and pregnancy associated plasma protein: A, in Bitola |